Treating insomnia: Current and investigational pharmacological approaches
- PMID: 16876255
- DOI: 10.1016/j.pharmthera.2005.04.014
Treating insomnia: Current and investigational pharmacological approaches
Abstract
Chronic insomnia affects a significant proportion of young adult and elderly populations. Treatment strategies should alleviate nighttime symptoms, the feeling of nonrestorative sleep, and impaired daytime function. Current pharmacological approaches focus primarily on GABA, the major inhibitory neurotransmitter in the central nervous system. Benzodiazepine receptor agonists (BzRA) have been a mainstay of pharmacotherapy; the classical benzodiazepines and non-benzodiazepines share a similar mode of action and allosterically enhance inhibitory chloride currents through the GABA(A) receptor, a ligand-gated protein comprising 5 subunits pseudosymmetrically arranged around a core anion channel. Variations in GABA(A) receptor subunit composition confer unique pharmacological, biophysical, and electrophysiological properties on each receptor subtype. Classical benzodiazepines bind non-selectively to GABA(A) receptors containing a gamma2 subunit, whereas non-benzodiazepine hypnotics bind with higher relative affinity to alpha1-containing receptors. The non-benzodiazepine compounds generally represent an improvement over benzodiazepines as a result of improved binding selectivity and pharmacokinetic profiles. However, the enduring potential for amnestic effects, next day residual sedation, and abuse and physical dependence, particularly at higher doses, underscores the need for new treatment strategies. Novel pharmacotherapies in development act on systems believed to be specifically involved in the regulation of the sleep-wake cycle. The recently approved melatonin receptor agonist, ramelteon, targets circadian mechanisms. Gaboxadol, an investigational treatment and a selective extrasynaptic GABA(A) receptor agonist (SEGA), targets GABA(A) receptors containing a delta subunit, which are located outside the synaptic junctions of thalamic and cortical neurons thought to play an important regulatory role in the onset, maintenance, and depth of the sleep process.
Similar articles
-
Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol. 2006 Feb;6(1):30-6. doi: 10.1016/j.coph.2005.10.004. Epub 2005 Dec 20. Curr Opin Pharmacol. 2006. PMID: 16368265 Review.
-
[New hypnotics: perspectives from sleep physiology].Vertex. 2007 Jul-Aug;18(74):294-9. Vertex. 2007. PMID: 18265473 Review. Spanish.
-
Mechanisms of sleep induction by GABA(A) receptor agonists.J Clin Psychiatry. 2007;68 Suppl 5:6-12. J Clin Psychiatry. 2007. PMID: 17539703 Review.
-
A physiologic basis for the evolution of pharmacotherapy for insomnia.J Clin Psychiatry. 2007;68 Suppl 5:13-8. J Clin Psychiatry. 2007. PMID: 17539704 Review.
-
Main neuroendocrine features and therapy in primary sleep troubles.Rev Med Chir Soc Med Nat Iasi. 2012 Jul-Sep;116(3):862-6. Rev Med Chir Soc Med Nat Iasi. 2012. PMID: 23272543
Cited by
-
Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes.PLoS One. 2015 Mar 23;10(3):e0120239. doi: 10.1371/journal.pone.0120239. eCollection 2015. PLoS One. 2015. PMID: 25798598 Free PMC article.
-
Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies.J Clin Sleep Med. 2010 Feb 15;6(1):30-9. J Clin Sleep Med. 2010. PMID: 20191935 Free PMC article. Clinical Trial.
-
The orthosteric GABAA receptor ligand Thio-4-PIOL displays distinctly different functional properties at synaptic and extrasynaptic receptors.Br J Pharmacol. 2013 Oct;170(4):919-32. doi: 10.1111/bph.12340. Br J Pharmacol. 2013. PMID: 23957253 Free PMC article.
-
Progress in GABAA receptor agonists for insomnia disorder.Front Pharmacol. 2024 Nov 5;15:1432726. doi: 10.3389/fphar.2024.1432726. eCollection 2024. Front Pharmacol. 2024. PMID: 39564117 Free PMC article. Review.
-
Succinic acid enhances sedative activity of diazepam through GABAergic receptor modulation: Evidence from behavioral approach and computational insights.Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug 21. doi: 10.1007/s00210-025-04538-5. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40839005
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical